Compile Data Set for Download or QSAR
maximum 50k data
Found 231 Enz. Inhib. hit(s) with all data for entry = 11153
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM384427(US10590114, No. 122 | US11111235, Compound 122 | U...)
Affinity DataIC50:  0.720nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM384405(US10590114, No. 108 | US11111235, No. 91 | US11591...)
Affinity DataIC50:  0.960nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM384428(US10590114, No. 115 | US11111235, Compound 114 | U...)
Affinity DataIC50:  1.05nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM384457(US10590114, No. 144 | US11111235, Compound 143 | U...)
Affinity DataIC50:  1.21nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM384464(US10590114, No. 151 | US11111235, Compound 150 | U...)
Affinity DataIC50:  1.22nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM384485(US10590114, No. 172 | US11111235, Compound 172 | U...)
Affinity DataIC50:  1.47nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM384432(US10590114, No. 118 | US11111235, Compound 118 | U...)
Affinity DataIC50:  1.55nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM384432(US10590114, No. 118 | US11111235, Compound 118 | U...)
Affinity DataIC50:  1.55nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM384407(US10590114, No. 93 | US11111235, No. 93 | US115913...)
Affinity DataIC50:  1.87nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM384469(US10590114, No. 156 | US11111235, Compound 155 | U...)
Affinity DataIC50:  1.95nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM384382(US10590114, No. 71 | US11111235, No. 69 | US115913...)
Affinity DataIC50:  2.23nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM384347(BDBM384370 | US10590114, No. 70 | US11111235, No. ...)
Affinity DataIC50:  2.31nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM384330(US10590114, No. 27 | US11111235, No. 27 | US115913...)
Affinity DataIC50:  3.41nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM384392(US10590114, No. 78 | US11111235, No. 78 | US115913...)
Affinity DataIC50:  3.69nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM384455(US10590114, No. 141 | US11111235, Compound 141 | U...)
Affinity DataIC50:  3.94nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM384310(US10590114, No. 14 | US11111235, No. 14 | US115913...)
Affinity DataIC50:  5.91nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM384287(US10590114, No. 1 | US11111235, No. 1 | US11591316...)
Affinity DataIC50: <30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM436211(US10590114, No. 3 | US11111235, No. 3 | US11591316...)
Affinity DataIC50: <30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM436212(US10590114, No. 4 | US11111235, No. 4 | US11591316...)
Affinity DataIC50: <30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM384294(US10590114, No. 5 | US11111235, No. 5 | US11591316...)
Affinity DataIC50: <30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM384297(US10590114, No. 7 | US11111235, No. 7 | US11591316...)
Affinity DataIC50: <30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM384299(US10590114, No. 8 | US11111235, No. 8 | US11591316...)
Affinity DataIC50: <30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM436217(US10590114, No. 9 | US11111235, No. 9 | US11591316...)
Affinity DataIC50: <30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM384307(US11591316, Compound 11 | US9932325, Example 11)
Affinity DataIC50: <30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM384308(US11591316, Compound 12 | US9932325, Example 12)
Affinity DataIC50: <30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM384309(US10590114, No. 13 | US11111235, No. 13 | US115913...)
Affinity DataIC50: <30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM384310(US10590114, No. 14 | US11111235, No. 14 | US115913...)
Affinity DataIC50: <30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM384311(US10590114, No. 15 | US11111235, No. 15 | US115913...)
Affinity DataIC50: <30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM384312(US10590114, No. 16 | US11111235, No. 16 | US115913...)
Affinity DataIC50: <30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM384314(US10590114, No. 17 | US11111235, No. 17 | US115913...)
Affinity DataIC50: <30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM196756(US10590114, No. 18 | US11111235, No. 18 | US115913...)
Affinity DataIC50: <30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM384317(US10590114, No. 19 | US11111235, No. 19 | US115913...)
Affinity DataIC50: <30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM384318(US10590114, No. 20 | US11111235, No. 20 | US115913...)
Affinity DataIC50: <30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM384321(US10590114, No. 21 | US11111235, No. 21 | US115913...)
Affinity DataIC50: <30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM384323(US10590114, No. 24 | US11111235, No. 24 | US115913...)
Affinity DataIC50: <30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM384323(US10590114, No. 24 | US11111235, No. 24 | US115913...)
Affinity DataIC50: <30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM384323(US10590114, No. 24 | US11111235, No. 24 | US115913...)
Affinity DataIC50: <30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM384328(US10590114, No. 25 | US11111235, No. 25 | US115913...)
Affinity DataIC50: <30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM384330(US10590114, No. 27 | US11111235, No. 27 | US115913...)
Affinity DataIC50: <30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM384330(US10590114, No. 27 | US11111235, No. 27 | US115913...)
Affinity DataIC50: <30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM384334(US10590114, No. 29 | US11111235, No. 29 | US115913...)
Affinity DataIC50: <30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM384334(US10590114, No. 29 | US11111235, No. 29 | US115913...)
Affinity DataIC50: <30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM384343(US10590114, No. 58 | US11111235, No. 32 | US115913...)
Affinity DataIC50: <30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM384346(US10590114, No. 33 | US11111235, No. 33 | US115913...)
Affinity DataIC50: <30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM384347(BDBM384370 | US10590114, No. 70 | US11111235, No. ...)
Affinity DataIC50: <30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM384349(US10590114, No. 35A | US11111235, No. 35A | US1159...)
Affinity DataIC50: <30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM384350(US10590114, No. 35B | US11111235, No. 35B | US1159...)
Affinity DataIC50: <30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM384352(US10590114, No. 37 | US11111235, No. 37 | US115913...)
Affinity DataIC50: <30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM384355(BDBM384364 | US10590114, No. 48 | US11111235, No. ...)
Affinity DataIC50: <30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM384356(US10590114, No. 39A | US11111235, No. 39A | US1159...)
Affinity DataIC50: <30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 231 total ) | Next | Last >>
Jump to: